Autosomal Recessive Disorders

AR inheritance requires the person to be homozygous for the disease-causing allele. If both parents are carriers (Aa x Aa), there is a 25% chance of an affected child (aa), a 50% chance of a carrier child (Aa), and a 25% chance of an unaffected non-carrier child (AA). AR disorders frequently involve mutations in genes that encode enzymes. In most enzymatic pathways, 50% of the normal enzyme level (found in carriers) is sufficient to maintain normal metabolic function, which is why carriers are asymptomatic. Clinically, AR disorders often present in childhood or infancy. Because these genes are on autosomes, both males and females are affected equally. A hallmark of AR inheritance in a pedigree is a 'horizontal' pattern, where several siblings are affected but the parents and children of the affected individuals are generally not. Consanguinity (reproduction between related individuals) significantly increases the risk of AR disorders because relatives are more likely to share the same rare recessive alleles from a common ancestor. UK population screening, such as the newborn blood spot (heel prick) test, focuses heavily on AR conditions like Cystic Fibrosis and MCADD to allow for early intervention.

The molecular basis of AR disorders is often a complete or near-complete loss of protein function. In Cystic Fibrosis, mutations in the CFTR gene lead to a defective chloride channel, causing thickened secretions. In Sickle Cell Anemia, a specific point mutation in the HBB gene (Glu6Val) leads to the production of abnormal hemoglobin (HbS) that polymerizes under low oxygen. Metabolic AR disorders, such as Phenylketonuria (PKU), result from the accumulation of toxic precursors or the deficiency of vital products. Compound heterozygosity occurs when an individual has two different mutant alleles at the same locus (e.g., two different CFTR mutations) that both result in a loss of function, leading to the disease phenotype just like a true homozygote.

AR disorders are major targets for screening and prevention. Carrier screening is offered to individuals with a family history or those in high-risk ethnic groups (e.g., Tay-Sachs in Ashkenazi Jewish populations). In the UK, the Guthrie test (newborn screening) is vital for early diagnosis of AR metabolic conditions. Clinicians should consider AR inheritance when multiple siblings are affected with a rare condition, especially if the parents are healthy but related. Patients with AR conditions like Hemochromatosis or Wilson’s disease may present in adulthood with organ failure, emphasizing the need for a high index of clinical suspicion.

1. Newborn blood spot screening (Heel prick). 2. Carrier testing for relatives of an affected individual. 3. Sweat test (for Cystic Fibrosis). 4. Specific enzyme assays (e.g., Hexosaminidase A for Tay-Sachs). 5. Molecular genetic analysis to identify specific biallelic mutations.

Management varies from dietary restriction (e.g., low phenylalanine diet in PKU) to organ-specific treatments (e.g., enzyme replacement therapy or lung physiotherapy in CF). Definitive management for some hematological AR disorders may include bone marrow transplant. Genetic counseling is essential to explain that if an affected person has children with a non-carrier partner, all children will be carriers but none will be affected.